Expression And Clinical Significance Of NPM/B23Protein And P53Protein In Endometrial Carcinoma

Objective:This study was to discuss the expression and clinical significance of NPM/B23protein and P53protein in endometrial carcinoma and non-tumorous tissue adjacent to endometrial carcinoma.Methods:60cases of endometrial carcinoma tissue samples diagnosed by the department of pathology of Jiangsu Subei People’s Hospital were selected. Immunohistochemical staining was used to determine the expression of NPM/B23protein and P53protein in60cases of endometrial carcinoma and non-tumorous tissue adjacent to endometrial carcinoma, and the correlation with the patients clinical and pathological features and prognosis was analyzed. All data were analyzed by SPSS16.0statistic software. Probability value of P<0.05was considered statistically significant.Results:1. The positive expression rates of NPM/B23protein in endometrial carcinoma tissue and the non-tumorous tissue adjacent to endometrial carcinoma were76.7%(46/60) and26.7%(16/60), and the positive expression rate of P53protein in endometrial carcinoma tissue and the non-tumorous tissue adjacent to endometrial carcinoma were40.0%(24/60) and0%(0/60). The expression of NPM/B23protein and P53protein in endometrial cancer tissue were significantly higher than that in the non-tumorous tissue adjacent to endometrial carcino, and the difference was statistically significant (P<0.01).2. The positive expression rate of NPM/B23protein was76.1%and78.6%respectively, and the difference was statistically significant (P<0.05). The positive expression rate of P53protein was21.7%and100%respectively, and the difference was statistically significant (P<0.05).3. The positive expression rate of NPM/B23in G1,G2and G3endometrial tissue were60.0%,82.8%and90.9%respectively, and the difference was statistically significant (P<0.05). The positive expression rate of P53in G1, G2and G3endometrial tissue were20.0%,34.5%and90.9%respectively. The positive expression rate of P53in G1was higher than that in G2, but the difference was not statistically significant (P>0.05). The positive expression rate of P53in G3was higher than that in G1and G2, and the difference was statistically significant (P<0.05).4. In the two groups of specimens without muscular infiltration and with muscular infiltration, the positive expression rate of NPM/B23were40.0%and84.0%respectively, the difference was statistically significant (P<0.05).Respectively, the positive expression rate of P53protein was10.0%and46.0%, and there was no statistically significant difference (P>0.05). The positive expression rate of NPM/B23in the two groups of specimens with shallow and deep muscularis infiltrating were45.5%and94.9%respectively, the positive expression rate of P53protein were9.1%and56.4%, and the differences were statistically significant (P <0.05).5. With the increase of endometrial cancer patients pathologically staging, the positive expression rates of NPM/B23protein and P53protein were also increased, but the difference was not statistically significant (P>0.05).6. The positive expression rate of NPM/B23in patients with and without lymph node metastasis were84.4%and67.9%respectively, there was no statistically significant difference (P>0.05). Respectively, the P53protein expression were68.8%and57.1%, and the difference was statistically significant(P<0.05).7. There was positive correlation between the expression of NPM/B23protein and P53protein (r=0.735, P<0.05).Conclusion:The expressions of NPM/B23and P53protein in the endometrial carcinoma tissue are significantly higher than that of adjacent non-tumorous tissue. There is a synergistic relationship between the expression of NPM/B23and P53protein in endometrial carcinoma. It is supported that united detection of NPM/B23and P53protein in endometrial carcinoma may conquer the weakness of poor sensitivity and low accuracy of single detection, and it may be helpful to the diagnosis, treatment and evaluating the prognosis of endometrial carcinoma.